Swiss AI Drug Trial Start-up Receives Funding From Spotify-Backer Creandum
5 Articles
5 Articles
Swiss AI drug trial start-up receives funding from Spotify-backer Creandum
ZURICH, Oct 27 (Reuters) - Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer of Spotify and Trade Republic, the company said...
Atlas Bio is improving the success rate of clinical trials, with 70 percent of all drugs failing so far, and the start-up is now collecting eleven million dollars.
Atlas Bio launches with $12.5M to eliminate animal testing and simulate Phase 2 trials - European Biotechnology Magazine
Switzerland-based Atlas Bio has emerged from stealth with $12.5 million in funding to develop AI simulations that predict drug responses, with the ambition of replacing parts of clinical development and animal testing.
Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing
Swiss tech-bio firm Atlas Bio today launched from stealth with a $10 million Seed round led by Creandum, alongside a previously unannounced pre-Seed round led by First Momentum Ventures and LEA Partne...
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
